-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $30

Benzinga·03/19/2026 13:55:45
Listen to the news
Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $25 to $30.